FDA approves new pain treatment device from Durham firm Bioventus
Durham-based Bioventus has received an OK from the U.S. Food and Drug Administration to market its next-generation pain treatment device.
Read MorePosted by WRAL TechWire | Mar 2, 2022
Durham-based Bioventus has received an OK from the U.S. Food and Drug Administration to market its next-generation pain treatment device.
Read MorePosted by Jason Parker | Nov 1, 2021
Bioventus has completed its transaction to acquire Misonix in a $518 million cash-and-stock deal, and it could acquire another company soon.
Read MorePosted by WRAL TechWire | Sep 2, 2021
The global orthobiologics company headquartered in Durham has agreed to make a $50 million escrow payment to Israeli med tech startup CertiHeal, “signaling its intent to move forward with the acquisition,” the company said.
Read MorePosted by Jason Parker | Aug 31, 2021
Bioventus plans to exercise an option to purchase an Israeli company, in which the company has invested $17.5 million previously across two rounds.
Read MorePosted by WRAL TechWire | Aug 26, 2021
Bioventus will lead a Series D round, with an undisclosed amount, as a strategic investor in Trice Medical, based in Pennsylvania. Bioventus will also receive exclusive sales and distribution rights as a part of the deal.
Read MorePosted by WRAL TechWire | Jul 31, 2021
Bioventus, a global orthobiologics company headquartered in Durham, will acquire Misonix, a New York-based developer of ultrasonic surgical devices, in a cash-and-stock transaction valued at about $518 million.
Read MorePosted by WRAL TechWire | Jul 15, 2021
Durham-based Bioventus, a global med tech company which went public earlier this year, is releasing a new product to its lineup that uses human tissue to improve bone fusions.
Read MorePosted by WRAL TechWire | Mar 31, 2021
Global medical technology company Bioventus, which went public earlier this year, is growing bigger with an acquisition. Here are the details.
Read MorePosted by WRAL News | Feb 26, 2021
Bioventus discovered that some of its sales reps were not properly completing Medicare claims forms and self-reported the problem, resulting in the $3.6M fine.
Read More